Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of two concurrent chemoradiotherapy regimens for esophageal squamous cell carcinoma
ChiCTR-TRC-12002719Phase 3Completed
- Sponsor
- Anyang Cancer Hospital
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, fluorouracil and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Anyang Cancer Hospital. Primary endpoint: progression-free survival. Started Nov 2012; status: completed.
02
Drugs
cisplatinfluorouracilpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-TRC-12002719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002719.